Michaloglou, C., Crafter, C., Siersbæk, R., Delpuech, O., Curwen, J., Carnevalli, L. S., . . . Cosulich, S. C. (2018). Combined inhibition of mTOR and CDK4/6 is required for optimal blockade of E2F function and long term growth inhibition in estrogen receptor positive breast cancer. Mol Cancer Ther.
Chicago Style CitationMichaloglou, Chrysiis, et al. "Combined Inhibition of MTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long Term Growth Inhibition in Estrogen Receptor Positive Breast Cancer." Mol Cancer Ther 2018.
Cita MLAMichaloglou, Chrysiis, et al. "Combined Inhibition of MTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long Term Growth Inhibition in Estrogen Receptor Positive Breast Cancer." Mol Cancer Ther 2018.